Smoking Tied to Higher Risk for Severe COVID-19
Smoking is associated with a higher risk for severe COVID-19, including death, independent of sociodemographic characteristics and medical history.
Smoking is associated with a higher risk for severe COVID-19, including death, independent of sociodemographic characteristics and medical history.
From 2018 to 2020, there was a slight decrease in electronic cigarette use among U.S. adults, especially among young adults aged 18 to 20 years, while daily e-cigarette use increased during the same period.
For men, smoking is associated with increased fracture risk.
In 2019, a majority of new daily tobacco users aged 14 to 17 years vaped daily.
A low-burden point-of-care intervention, featuring an ELEVATE is associated with increased reach and effectiveness of smoking cessation treatment.
The prevalence of adolescent vaping is 8.6% in 47 lower-middle, upper-middle, and high-income countries, and the prevalence of frequent vaping is 1.7%.
There were significant reductions in the prevalence of self-reported cigarette smoking among U.S. adults with major depressive episode (MDE), substance use disorder (SUD), or both between 2006 and 2019.
For patients with established atherosclerotic cardiovascular disease, the treatment benefit of smoking cessation is equivalent to the use of targeted pharmaceutical interventions in persistent smokers.
From 2019 to 2020, there was a decrease in the prevalence of overall tobacco product use.
Authors outline treatment strategies for hidradenitis suppurativa with a focus on diet and lifestyle management for all stages of this disorder.